In certain trials, the TNFa (tumour necrosis factor alpha) antibody therapy seems to improve the endothelial dysfunction and vascular stiffness and to downregulate the mucosal angiogenesis in this population [15,16,17,18]. The gene discussed is TNF; the disease is endothelial dysfunction.